Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG Sequential NAL-IRI + 5-FU/LV With or Without Camrelizumab in Conversion Therapy for Locally Advanced Pancreatic Cancer
ChiCTR2600122521Phase 2Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Apr 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paclitaxel, gemcitabine, irinotecan liposome, fluorouracil, folinic acid and 1 more in pancreatic cancer (PC) (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: R0 resection rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
paclitaxelgemcitabineirinotecan liposomefluorouracilfolinic acid
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2600122521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122521.